Price$124.22+1.16 (+0.94%)
01:30 PM07:45 PM
News · 26 weeks84+10%
2025-12-142026-06-07
Mix4990d
- Insider34(69%)
- Other7(14%)
- SEC Filings6(12%)
- Earnings2(4%)
Latest news
25 items- SECGlaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - GLAUKOS Corp (0001192448) (Filer)
- INSIDERDirector Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- SECSEC Form SD filed by Glaukos CorporationSD - GLAUKOS Corp (0001192448) (Filer)
- INSIDERDirector Hoffmeister David F exercised 15,000 shares at a strike of $24.69, increasing direct ownership by 46% to 47,671 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Kliman Gilbert H sold $703,800 worth of shares (5,000 units at $140.76) and exercised 5,000 shares at a strike of $24.69 (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Kliman Gilbert H exercised 5,000 shares at a strike of $24.69 and sold $675,000 worth of shares (5,000 units at $135.00) (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- PRGlaukos Announces Participation in Upcoming Investor ConferencesGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at 1:00 p.m. ET in Chicago, IL Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 a.m. ET in New York City, NY Truist MedTech Conference on Tuesday, June 16, 2026, at 9:20 a.m. ET in Boston, MA A live an
- INSIDERSVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,400,000 worth of shares (10,000 units at $140.00) as part of a pre-agreed trading plan (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERPRESIDENT & COO Gilliam Joseph E sold $2,809,508 worth of shares (19,573 units at $143.54), decreasing direct ownership by 21% to 73,419 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- INSIDERDirector Wen Leana sold $243,695 worth of shares (1,700 units at $143.35), decreasing direct ownership by 8% to 19,739 units (SEC Form 4)4 - GLAUKOS Corp (0001192448) (Issuer)
- SECGlaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - GLAUKOS Corp (0001192448) (Filer)
- SECSEC Form 10-Q filed by Glaukos Corporation10-Q - GLAUKOS Corp (0001192448) (Filer)
- SECSEC Form SCHEDULE 13G filed by Glaukos CorporationSCHEDULE 13G - GLAUKOS Corp (0001192448) (Subject)
- SECGlaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - GLAUKOS Corp (0001192448) (Filer)
- PRGlaukos Announces First Quarter 2026 Financial ResultsGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record net sales of $129.3 million in Q1 2026 increased 47% year-over-year. U.S. Glaucoma record net sales of $93.5 million in Q1 2026 increased 58% year-over-year. Gross margin of approximately 78% and non-GAAP gross margin of approxim
- PRGlaukos Announces the Release of its 2025 Sustainability ReportGlaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. "I am proud to issue our seventh annual Sustainability Report, which highlights the meaningful progress we continue to make in advancing our core corporate sustainability initiatives that are aligned with our mission and key strategic plans," said
- SECSEC Form DEF 14A filed by Glaukos CorporationDEF 14A - GLAUKOS Corp (0001192448) (Filer)
- SECSEC Form DEFA14A filed by Glaukos CorporationDEFA14A - GLAUKOS Corp (0001192448) (Filer)
- PRGlaukos Receives Permanent J-code for Epioxa™New J-code for Epioxa™, J2789, set to become effective July 1, 2026 Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ ("Epioxa") for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. The new J-code for Epioxa, J2789, is set to become effective July 1, 2026. It is expected to streamline the
GKOS FAQ
7 questionsWhat does Glaukos Corporation do?
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure...Where does GKOS stock trade?
Glaukos Corporation (GKOS) is listed on NYSE.What sector and industry is GKOS in?
Glaukos Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Glaukos Corporation go public?
Glaukos Corporation (GKOS) completed its IPO in 2015.What are analysts saying about GKOS?
Glaukos Corporation has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight on 2025-10-27.What companies are similar to GKOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare GKOS side-by-side with any of them on Quantisnow.How can I track GKOS on Quantisnow?
Quantisnow aggregates Glaukos Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GKOS to receive live email and push alerts on every new disclosure.